Search

Your search keyword '"Michael Koenigsmann"' showing total 4 results
Start Over Author "Michael Koenigsmann" Publisher springer science and business media llc
4 results on '"Michael Koenigsmann"'

1. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation

Author

Arnold Kloos, Ulrich Lehmann, Christian Thiede, Anuhar Chaturvedi, Birgit Markus, U. Platzbecker, V Panagiota, Matthias Eder, Haefaa Alchalby, N Kröger, Arne Trummer, Felicitas Thol, Arnold Ganser, Gudrun Göhring, Anita Badbaran, Brigitte Schlegelberger, Tobias Schroeder, Michael Koenigsmann, H-H Kreipe, Boris Fehse, Christian Koenecke, Michael Stadler, Guido Kobbe, Rabia Shahswar, and Michael Heuser

Subjects
Cancer Research, medicine.medical_treatment, Treatment outcome, Graft vs Host Disease, Hematopoietic stem cell transplantation, medicine.disease_cause, Homologous chromosome, medicine, Humans, Transplantation, Homologous, In patient, Myelofibrosis, Mutation, biology, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, Prognosis, medicine.disease, Transplantation, Treatment Outcome, surgical procedures, operative, Oncology, Primary Myelofibrosis, Immunology, biology.protein, Cancer research, Calreticulin, business
Abstract

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation

Published
2014

2. Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial

Author

Bernd Metzner, Leopold Balleisen, Michael Stadler, Maximilian Christopeit, Axel Hinke, Gerhard Behre, Michael Koenigsmann, Albrecht Reichle, Lutz Uharek, Christoph Kahl, R Hinke, Nadezda Basara, Herbert G. Sayer, Arnold Ganser, Dietger Niederwieser, Sebastian Theurich, Jochen Casper, and Martin Mohren

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Transplantation Conditioning, Allogeneic transplantation, Adolescent, education, Treosulfan, Transplantation, Autologous, Carboplatin, Antibodies, Monoclonal, Murine-Derived, Young Adult, International Prognostic Index, Recurrence, Risk Factors, DHAP, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Mucositis, Humans, Transplantation, Homologous, Prospective Studies, Busulfan, Etoposide, Aged, Transplantation, business.industry, Lymphoma, Non-Hodgkin, Hematology, Middle Aged, Prognosis, medicine.disease, Fludarabine, Surgery, Treatment Outcome, Disease Progression, Female, Rituximab, business, Stem Cell Transplantation, medicine.drug
Abstract

Since the outcome of relapsed/refractory aggressive non-Hodgkin’s lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP, patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (>1 year after first CR who achieved CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory disease, 32% early and 32% late relapse. During DHAP treatment, progression occurred in 32% of patients. Of 33 patients who received TEC, 5 received second TEC and 15 allogeneic transplantation. Main toxicity after TEC was oral mucositis (CTC grades 3 and 4 in 50% and 13%, respectively). In total, 42% patients achieved CR. Median OS was 21.4 months for all patients and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative at predicting OS (P

Published
2013

3. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation

Author

M. U. Heim, J Casper, E Becker, Astrid Franke, Kathleen Jentsch-Ullrich, Martin Mohren, M Freund, and Michael Koenigsmann

Subjects
Adult, Male, Melphalan, medicine.medical_specialty, Lymphoma, ThioTEPA, Treosulfan, Transplantation, Autologous, Gastroenterology, Refractory, Recurrence, Internal medicine, medicine, Mucositis, Humans, Autologous transplantation, Antineoplastic Agents, Alkylating, Busulfan, Etoposide, Transplantation, business.industry, Hematology, Middle Aged, medicine.disease, Hematopoietic Stem Cell Mobilization, Surgery, Female, business, Stem Cell Transplantation, medicine.drug
Abstract

This phase I/II study evaluated high-dose treosulfan in patients with high-grade lymphoma. In all, 21 patients (median age 51, 25-60 years) with primary refractory disease (n=3) or early (n=11) or late (n=7) relapse received DexaBEAM and one course etoposide for cytoreduction and PBPC mobilization. Subsequently, 16 patients received 30 g/m2 treosulfan and 140 mg/m2 melphalan, followed by autologous transplantation. Nine patients received a 2nd high-dose treatment (HDT) with 30 g/m2 treosulfan and 750 mg/m2 thiotepa. Recovery time to >1/nl leukocytes and >25/nl thrombocytes was 8.9 (range 8-11) and 11.9 (8-16) days after 1st and 9.6 (7-13) and 13 (9-19) days after 2nd HDT. Reversible grade 3 or 4 nonhematologic toxicities included mucositis (n=7), infection (n=7) and one episode of re-entry tachycardia. Two treatment-related deaths occurred after 2nd HDT. Since three dose-limiting toxicities occurred among nine patients receiving tandem HDT, 30 g/m2 of treosulfan was considered MTD in this setting. Patients with late compared to early relapse or refractory disease had a higher probability of CR (6/7 vs 3/14 patients, P=0.017) and overall survival (71 vs 21%, P

Published
2004

4. Acute leukaemia in adults: researching the patient's perspective

Author

Michael Koehler, Jörg Frommer, Michael Koenigsmann, and Astrid Franke

Subjects
Adult, Physician-Patient Relations, Cancer Research, medicine.medical_specialty, Leukemia, Psychotherapist, Depression, business.industry, Perspective (graphical), Hematology, Anxiety, Oncology, Acute Disease, Adaptation, Psychological, Quality of Life, medicine, Humans, Psychiatry, business, Stress, Psychological
Published
2005

Catalog

Books, media, physical & digital resources
See catalog results